Sharemaestro company-news research for Harmony Biosciences Holdings (HRMY), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
NASDAQ
United States
Measured evidence
Company news sentiment
HRMY news sentiment
Harmony Biosciences Holdings
Company headlines compared by relevance, subject, source independence, tone and the market's completed price response.
Weighted tone66Neutral is 50
Constructive news tone
66/100 evidence confidence
100% direct company focus
5 current stories across 1 publishers
Current company news
News confirmed by price
Constructive news tone is drawn from 5 fresh independent stories, including 5 company-specific items across 1 publishers.
Latest source headline BridgeBio Q2 Earnings Miss, Revenues Beat as Attruby Sales Surge finance.yahoo.com · 11 Aug 2026 16:45What supports the read
5 current stories are mapped specifically to HRMY.
Cross-story agreement is 85/100, indicating a comparatively coherent tape.
Constructive news tone is being confirmed by positive weekly price action.
What tempers the read
Only 1 publisher currently contribute to the measured read.
66/100
Weighted toneConstructive news tone
66/100
Evidence confidencesolid confidence
100%/100
Company focus5 direct stories
85/100
Evidence agreement15/100 dispersion
News history
Tone and story flow over 21 days
24 Jul03 Aug13 Aug
Weighted toneStory volumeNeutral 50
Evidence confidence
What supports the score
Confidence rises through sample depth, independent publishers, direct company relevance, freshness and agreement. A high or low tone score is not itself evidence of reliability.
Sample depth61
4.88 effective storiesSource breadth20
1 independent publishersDirect relevance100
company-specific evidence shareFreshness59
recency-weighted evidenceAgreement85
cross-story consistencySource independence0
lower publisher concentrationPrice context
Sentiment against the 26-week price path
Constructive news tone is being confirmed by positive weekly price action.
13 Feb15 May07 Aug
Weekly close, indexedSentiment score
Sentiment confirms active trend
News subjects
What is shaping the score
Earnings704 stories · 80%
Regulatory and legal881 stories · 20%
Source mix
Where the evidence comes from
finance.yahoo.com745 stories · 100%
Recurring subjects
Subjects appearing most often
Earnings5Biotech5Earnings Per Share4Fda Approval3Clinical Trials2Regulation1Price Target1Pharma1Oncology1Net Income1
Earlier readings
How the score has changed
ConstructiveBalanced or withheldCautious
Source headlines
The news behind the score
Every row shows the public evidence used to understand the read. Direct company stories carry more weight than industry or sector context; duplicate coverage is consolidated before scoring.
#159Tone
finance.yahoo.comDirect company coverage
BridgeBio Q2 Earnings Miss, Revenues Beat as Attruby Sales Surge
BridgeBio Pharma BBIO reported a second-quarter 2026 loss of 78 cents per share, wider than the Zacks Consensus Estimate of a loss of 64 cents. Despite the miss, the figure improved compared to the year-ago loss of 95 cents. Revenues surged 120% year over year to $243.7 million, beating the Zacks Consensus Estimate of $222.6 million. This growth was primarily driven by its sole marketed drug, Attruby. Year to date, BridgeBio's shares have gained 11% compared with the industry's 7% growth.Zacks Investment Research Image Source: Zacks Investment Research BBIO's Attruby Sales Drive the Top Line A
BiotechClinical TrialsEarningsEarnings Per ShareEarnings ResultsFda Approval
- Published
- 11 Aug 2026 16:45
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#251Tone
finance.yahoo.comDirect company coverage
ANIP Tops Q2 Earnings, Stock Down on Cortrophin Sales View Cut
ANI Pharmaceuticals ANIP reported second-quarter 2026 adjusted EPS of $2.21, beating the Zacks Consensus Estimate of $2.01. The reported figure rose 23% year over year, driven by higher sales during the quarter. Quarterly revenues totaled $266 million, up 26% from the year-ago period. The metric also beat the Zacks Consensus Estimate of $262.7 million. The quarter reflected solid execution across the portfolio, led by continued momentum for Purified Cortrophin Gel and contributions from a newly monetized intellectual property licensing arrangement. ANI's Rare Disease Business Shows Mixed Trend
BiotechEarningsFourth QuarterGuidancePharmaPrice Target
- Published
- 10 Aug 2026 17:05
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#387Tone
finance.yahoo.comDirect company coverage
OTLK Up More Than 300% in 3 Months: Here's What You Should Know
Shares of Outlook Therapeutics OTLK have witnessed a significant surge over the past three months, primarily driven by growing investor optimism related to the company's sole product, Lytenava, which is approved for the treatment of patients with wet age-related macular degeneration (wet AMD). OTLK's Price Performance Shares of Outlook Therapeutics have skyrocketed 311.8% in the past three months compared with the industry's increase of 6.9%.Zacks Investment Research Image Source: Zacks Investment Research Last month, the FDA approved Lytenava for the treatment of neovascular age-related macul
BiotechEarningsEarnings Per ShareFda Approval
- Published
- 10 Aug 2026 15:27
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#488Tone
finance.yahoo.comDirect company coverage
Here's Why Replimune Stock Skyrockets Nearly 223% in 3 Months
Shares of Replimune Group REPL have surged nearly 223% over the past three months, as the company steadily advanced its lead oncolytic immunotherapy, RP1 (vusolimogene oderparepvec), toward regulatory approval and strengthened the broader pipeline. The rally has been driven primarily by a series of positive regulatory developments that substantially reduced uncertainty surrounding RP1's path to commercialization. FDA Approves REPL's RP1 for Advanced Melanoma Earlier this month, the FDA granted accelerated approval to RP1 (vusolimogene oderparepvec) under the brand name Tudriqev, in combination
BiotechEarningsEarnings Per ShareFda ApprovalOncologyRegulation
- Published
- 10 Aug 2026 14:17
- Catalyst
- Regulatory and legal
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#581Tone
finance.yahoo.comDirect company coverage
Harmony Biosciences (HRMY) Is Up 9.0% After Q2 Earnings Jump And Pipeline Progress - What's Changed
Harmony Biosciences Holdings, Inc. recently reported second-quarter 2026 results showing net income of US$75.43 million, up from US$39.78 million a year earlier, with basic earnings per share from continuing operations rising to US$1.30 from US$0.69. Alongside these stronger earnings, the company reported progress across its neurology pipeline and clinical trials for rare neurological diseases, which could influence how investors view the balance between its current cash-generating products and longer-term development assets. We'll now examine how Harmony's sharp year-over-year earnings improv
BiotechClinical TrialsEarningsEarnings Per ShareEarnings ReleaseNet Income
- Published
- 07 Aug 2026 23:13
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
Earlier company news
HRMY news archive
Stored newest first for historical research. These older headlines are retained for reference and do not contribute to the current sentiment gauge above.
Aug
05
2026
simplywall.stArchivedPositive tone
Harmony Biosciences (HRMY) Stock Jumps On Profit Surge As Margin Pressure Lingers
- Published
- 5 Aug 2026 08:45
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
02
2026
simplywall.stArchivedPositive tone
Harmony Biosciences (HRMY) Stock Looks Below Fair Value On Earnings
- Published
- 2 Aug 2026 09:09
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
01
2026
GuruFocusArchivedPositive tone
HRMY Maintained by Mizuho -- Price Target Raised to $51.00
- Published
- 1 Aug 2026 11:25
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
31
2026
Market sourceArchivedPositive tone
Should Value Investors Buy Harmony Biosciences (HRMY) Stock?
- Published
- 31 Jul 2026 01:16
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
27
2026
Simply Wall StreetArchivedPositive tone
Did CFO Exit and Reaffirmed 2026 Guidance Just Shift Harmony Biosciences' (HRMY) Investment Narrative?
- Published
- 27 Jul 2026 03:14
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
25
2026
Kavout | AIArchivedPositive tone
Is Harmony Biosciences' Growth Story Still Compelling in 2026
- Published
- 25 Jul 2026 07:21
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
21
2026
Investing.comArchivedPositive tone
H.C. Wainwright reiterates Harmony Biosciences stock rating on demand beat
- Published
- 21 Jul 2026 01:38
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
18
2026
simplywall.stArchivedPositive tone
Harmony Biosciences Holdings (HRMY) Is Down 8.3% After Reaffirming 2026 Guidance And CFO Transition - Has The Bull Case Changed?
- Published
- 18 Jul 2026 18:19
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
18
2026
TradingViewArchivedPositive tone
HRMY Posts Preliminary Q2 Revenues, Announces CFO Transition
- Published
- 18 Jul 2026 16:49
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
15
2026
ZacksArchivedPositive tone
Zacks.com featured highlights Harmony, StoneCo, General Motors, Hewlett and Nexa
- Published
- 15 Jul 2026 13:26
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
14
2026
Market sourceArchivedNeutral tone
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Published
- 14 Jul 2026 06:26
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
11
2026
The Globe and MailArchivedNeutral tone
Wall Street Analysts Are Bullish on Top Healthcare Picks
- Published
- 11 Jul 2026 10:42
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
06
2026
TradingViewArchivedNeutral tone
Price to sales forward of Harmony Biosciences Holdings, Inc. – NASDAQ:HRMY
- Published
- 6 Jul 2026 04:58
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
03
2026
Stock TitanArchivedNeutral tone
25,000-share option exercise; affiliate sales reported — HRMY
- Published
- 3 Jul 2026 13:32
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
02
2026
simplywall.stArchivedNeutral tone
Is Harmony Biosciences (HRMY) Quietly Recasting Its Single-Drug Story Into a Broader Neuroscience Platform?
- Published
- 2 Jul 2026 04:00
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
01
2026
MT NewswiresArchivedNeutral tone
Deutsche Bank Adjusts Price Target on Harmony Biosciences to $36 From $30, Maintains Hold Rating
- Published
- 1 Jul 2026 01:55
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
28
2026
GuruFocusArchivedNeutral tone
Harmony Biosciences Holdings Inc (HRMY) Stock Forecast, Price Targets and Analysts Predictions
- Published
- 28 Jun 2026 06:39
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
27
2026
Stock Traders DailyArchivedNeutral tone
The Technical Signals Behind (HRMY) That Institutions Follow
- Published
- 27 Jun 2026 20:52
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
27
2026
Stock TitanArchivedPositive tone
HRMY affiliate gives notice to sell 45,594 shares (NASDAQ: HRMY)
- Published
- 27 Jun 2026 09:00
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
24
2026
AD HOC NEWSArchivedNeutral tone
Harmony Biosciences Stock - Analyst consensus and technical backdrop
- Published
- 24 Jun 2026 06:22
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
20
2026
TradingKeyArchivedNeutral tone
Harmony Biosciences Holdings Inc (HRMY) Valuation: PE, PB & Fair Value Analysis
- Published
- 20 Jun 2026 06:42
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
How the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean a balanced tape or that direction has been withheld for insufficient evidence; the status label distinguishes them.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
The page describes completed evidence available at the stated time. It is research context, not a forecast, recommendation, target or execution instruction.